BMRN
What one share of Biomarin Pharmaceutical holds
Pharmaceutical Preparations
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline.
Biomarin Pharmaceutical’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $17.37 |
|---|---|
| Profit | $0.39 |
| Capex (buildings and equipment) | $0.61 |
| Free cash flow | $3.76 |
| Cash and investments | $4.52 |
| Debt | $21.63 |
| Book value | $32.66 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $6.72 | −$3.81 | $0.89 | −$2.26 | — | $16.02 |
| 2017 | $7.53 | −$0.67 | $1.14 | −$1.19 | — | $15.97 |
| 2018 | $8.41 | −$0.44 | $0.82 | −$0.70 | — | $16.65 |
| 2019 | $9.52 | −$0.13 | $0.81 | −$0.54 | — | $17.36 |
| 2020 | $9.71 | $4.50 | $0.60 | −$0.15 | — | $22.56 |
| 2021 | $10.10 | −$0.35 | $0.52 | $1.14 | — | $23.19 |
| 2022 | $11.09 | $0.75 | $0.64 | $0.29 | — | $24.71 |
| 2023 | $12.63 | $0.88 | $0.50 | $0.33 | — | $26.25 |
| 2024 | $14.51 | $2.21 | $0.43 | $2.48 | — | $29.66 |
| 2025 | $16.32 | $1.80 | $0.52 | $3.67 | — | $31.65 |